| BIOGEN INC. DL -,0005 | 221.4000 / -0.27% |
| Date/Time | 01/21 / 16:35 |
| Chg. / Chg.(%) | -0.6000 / -0.27% |
| Bid | - |
| Ask | - |
| Open | 222.1000 |
| Previous Close | 222.0000 |
| High | 224.4000 |
| Low | 221.4000 |
| Volume [EUR] | 122,299.9000 |
| Volume [Units] | 547 |
| Price fixings | 11 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | Frankfurt |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 270.1200 |  |
806,526 |
| IEX | 270.10 | |
51,904 |
| Cboe US | 270.13 | |
24,867 |
| London Inter.. | 268.49 | |
2,363 |
| TradeGate | 221.350 | |
1,108 |
| Xetra | 221.85 |  |
604 |
| Frankfurt | 221.4000 | |
547 |
| Stuttgart | 222.050 | |
147 |
| Vienna Globa.. | 221.65 | |
136 |
| gettex | 221.450 | |
117 |
| München | 222.80 | |
0 |
| Hamburg | 222.00 | |
0 |
| Düsseldorf | 220.75 | |
0 |
| Berlin | 221.15 | |
0 |
| Hannover | 222.00 | |
0 |
| Lang & Schwa.. | 220.550 | |
|
| Mexico | 5,408.00 | |
11 |
News
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
12/10/2020 / 04:30 - GlobeNewswire
Real-time